Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study
Authors
Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
Mark T. Gladwin (ORCID: https://orcid.org/0000-0001-7267-9006)
John G.F. Cleland (ORCID: https://orcid.org/0000-0002-1471-7016)
Barry A. Borlaug (ORCID: https://orcid.org/0000-0001-9375-0596)
Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study
Sanjiv J. Shah, Mark T. Gladwin, John G.F. Cleland, Barry A. Borlaug et al.
Citations
7 citations
Journal
Circulation Heart Failure
Topics
Heart Failure Treatment and Management
Field-Weighted Citation Impact (FWCI)
9.72
article
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study
Sanjiv J. Shah, Mark T. Gladwin, John G.F. Cleland, Barry A. Borlaug, Faiez M. Zannad, Wentao Lu, Diana Bonderman, Adriaan A. Voors, Gabriela Lack
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
Circulation Heart FailureVol. 18(3)
Institutions
Northwestern University (US), University of Maryland, Baltimore (US), Johnson & Johnson (United States) (US), Mayo Clinic (US), University Medical Center Groningen (NL), Inserm (FR), British Heart Foundation (GB), Wiener Krankenanstaltenverbund (AT), Université de Lorraine (FR)